Neurofit Selects Mirae Asset Daewoo as IPO Lead Manager: "Targeting Listing Next Year"

[Asia Economy Reporter Hyunseok Yoo] Neurophiet, a specialized AI solution company for brain diseases, announced on the 23rd that it has signed an underwriting agreement with Mirae Asset Daewoo. The company plans to undergo a technology evaluation in the second half of this year and apply for listing in the second half of next year.

Neurophiet provides comprehensive medical solutions related to brain diseases, from diagnosis to treatment guidance and therapy for conditions such as dementia and stroke, utilizing its self-developed AI-based ‘Neurophet SegEngine’.

Until now, programs used for MRI brain image analysis have relied on Western standard brain models, failing to reflect racial differences and requiring several hours for analysis, showing limitations. In contrast, the Neurophet SegEngine can segment and analyze brain images within one minute regardless of race, age, or gender.

Additionally, Neurophiet’s brain disease imaging analysis software ‘NEUROPHET AQUA’ enables early detection of brain diseases by compartmentalizing MRI brain images, which were difficult to diagnose visually, and analyzing atrophy. Since the second half of last year, it has been supplied to various medical institutions and screening centers, with plans to expand sales channels.

Bin Jungil, CEO of Neurophiet, stated, "The MRI image analysis market is growing annually, with the neurological field accounting for the largest share. Having focused on brain science since graduate school, I am confident in our technological capabilities." He added, "Starting with the selection of the underwriting firm, we will prepare thoroughly for the technology evaluation in the second half of the year and successfully list on the KOSDAQ market next year."

This content was produced with the assistance of AI translation services.